Iteos Therapeutics Inc
NASDAQ:ITOS

Watchlist Manager
Iteos Therapeutics Inc Logo
Iteos Therapeutics Inc
NASDAQ:ITOS
Watchlist
Price: 8.2 USD -7.13%
Market Cap: 299.5m USD
Have any thoughts about
Iteos Therapeutics Inc?
Write Note

Intrinsic Value

ITOS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ITOS stock under the Base Case scenario is 4.12 USD. Compared to the current market price of 8.2 USD, Iteos Therapeutics Inc is Overvalued by 50%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ITOS Intrinsic Value
4.12 USD
Overvaluation 50%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Iteos Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ITOS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ITOS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Iteos Therapeutics Inc

Provide an overview of the primary business activities
of Iteos Therapeutics Inc.

What unique competitive advantages
does Iteos Therapeutics Inc hold over its rivals?

What risks and challenges
does Iteos Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Iteos Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Iteos Therapeutics Inc.

Provide P/S
for Iteos Therapeutics Inc.

Provide P/E
for Iteos Therapeutics Inc.

Provide P/OCF
for Iteos Therapeutics Inc.

Provide P/FCFE
for Iteos Therapeutics Inc.

Provide P/B
for Iteos Therapeutics Inc.

Provide EV/S
for Iteos Therapeutics Inc.

Provide EV/GP
for Iteos Therapeutics Inc.

Provide EV/EBITDA
for Iteos Therapeutics Inc.

Provide EV/EBIT
for Iteos Therapeutics Inc.

Provide EV/OCF
for Iteos Therapeutics Inc.

Provide EV/FCFF
for Iteos Therapeutics Inc.

Provide EV/IC
for Iteos Therapeutics Inc.

Show me price targets
for Iteos Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Iteos Therapeutics Inc?

How accurate were the past Revenue estimates
for Iteos Therapeutics Inc?

What are the Net Income projections
for Iteos Therapeutics Inc?

How accurate were the past Net Income estimates
for Iteos Therapeutics Inc?

What are the EPS projections
for Iteos Therapeutics Inc?

How accurate were the past EPS estimates
for Iteos Therapeutics Inc?

What are the EBIT projections
for Iteos Therapeutics Inc?

How accurate were the past EBIT estimates
for Iteos Therapeutics Inc?

Compare the revenue forecasts
for Iteos Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Iteos Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Iteos Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Iteos Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Iteos Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Iteos Therapeutics Inc with its peers.

Analyze the financial leverage
of Iteos Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Iteos Therapeutics Inc.

Provide ROE
for Iteos Therapeutics Inc.

Provide ROA
for Iteos Therapeutics Inc.

Provide ROIC
for Iteos Therapeutics Inc.

Provide ROCE
for Iteos Therapeutics Inc.

Provide Gross Margin
for Iteos Therapeutics Inc.

Provide Operating Margin
for Iteos Therapeutics Inc.

Provide Net Margin
for Iteos Therapeutics Inc.

Provide FCF Margin
for Iteos Therapeutics Inc.

Show all solvency ratios
for Iteos Therapeutics Inc.

Provide D/E Ratio
for Iteos Therapeutics Inc.

Provide D/A Ratio
for Iteos Therapeutics Inc.

Provide Interest Coverage Ratio
for Iteos Therapeutics Inc.

Provide Altman Z-Score Ratio
for Iteos Therapeutics Inc.

Provide Quick Ratio
for Iteos Therapeutics Inc.

Provide Current Ratio
for Iteos Therapeutics Inc.

Provide Cash Ratio
for Iteos Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Iteos Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Iteos Therapeutics Inc?

What is the current Free Cash Flow
of Iteos Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Iteos Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Iteos Therapeutics Inc

Current Assets 626.6m
Cash & Short-Term Investments 571.3m
Receivables 42.3m
Other Current Assets 13m
Non-Current Assets 125.2m
Long-Term Investments 107.8m
PP&E 10.8m
Other Non-Current Assets 6.6m
Current Liabilities 34.7m
Accounts Payable 11.1m
Accrued Liabilities 22m
Other Current Liabilities 1.6m
Non-Current Liabilities 53.3m
Other Non-Current Liabilities 53.3m
Efficiency

Earnings Waterfall
Iteos Therapeutics Inc

Revenue
35m USD
Operating Expenses
-179.8m USD
Operating Income
-144.8m USD
Other Expenses
36.7m USD
Net Income
-108.1m USD

Free Cash Flow Analysis
Iteos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ITOS Profitability Score
Profitability Due Diligence

Iteos Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Positive 3-Year Average ROE
Negative 1-Year Revenue Growth
37/100
Profitability
Score

Iteos Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ITOS Solvency Score
Solvency Due Diligence

Iteos Therapeutics Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
74/100
Solvency
Score

Iteos Therapeutics Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ITOS Price Targets Summary
Iteos Therapeutics Inc

Wall Street analysts forecast ITOS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ITOS is 35.19 USD with a low forecast of 25.25 USD and a high forecast of 48.3 USD.

Lowest
Price Target
25.25 USD
208% Upside
Average
Price Target
35.19 USD
329% Upside
Highest
Price Target
48.3 USD
489% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ITOS?

Click here to dive deeper.

Dividends

Iteos Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ITOS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

ITOS News

Profile

Iteos Therapeutics Inc Logo
Iteos Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

322.5m USD

Dividend Yield

0%

Description

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

Contact

MASSACHUSETTS
Watertown
321 Arsenal Street, Bldg 312, Floor 3, Suite 301
+18572044583.0
www.iteostherapeutics.com

IPO

2020-07-24

Employees

94

Officers

President, CEO & Director
Dr. Michel Detheux Ph.D.
Chief Financial Officer
Mr. Matthew Gall
Chief Operating Officer
Mr. Matthew A. Call M.B.A.
Chief Scientific Officer
Dr. Yvonne McGrath Ph.D.
Executive Vice President of Legal
Ms. Adi Osovsky
Executive Vice President of Human Resources
Mr. Philippe Brantegem
Show More
Chief Medical Officer
Dr. David Feltquate M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ITOS stock?

The intrinsic value of one ITOS stock under the Base Case scenario is 4.12 USD.

Is ITOS stock undervalued or overvalued?

Compared to the current market price of 8.2 USD, Iteos Therapeutics Inc is Overvalued by 50%.

Back to Top